# Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

> **NCT05463224** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Se-Hoon Lee** · enrollment: 150 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Lazertinib group

## Key facts

- **NCT ID:** NCT05463224
- **Lead sponsor:** Se-Hoon Lee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-04
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05463224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05463224, "Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05463224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*